Investigation of the Validity and Reliability of the Kinesthetic and Visual Imagery Questionnaire in Children With Duchenne Muscular Dystrophy

• ClinicalTrials.gov Identifier: NCT05559710
• Recruitment Status: Not yet recruiting
• First Posted: September 29, 2022
• Sponsor: Hacettepe University
• Information provided by (Responsible Party): Merve Bora, Hacettepe University

Study Description

Brief Summary:

Motor imagery (MI) can be defined as a dynamic process in which the person is mentally stimulated without performing the given motor movement. Studies of imagery; demonstrated that it alters a person's ability to learn, performance skills, and important cognitive skills (self-efficacy, self-confidence, effort, motivation). In recent years, it has been shown that motor imagery techniques are used for therapeutic purposes as a current neurorehabilitation approach and that imagery can have positive effects on improving motor activity and functions. However, it has been reported that the biggest difficulty in the use of imagery techniques is the inability to determine to what extent the individual can perform mental representation of movements. For this reason, it is thought that it is necessary to evaluate the motor imagery ability first in order to identify the patients who are suitable for motor imagery training. The Kinesthetic and Visual Imagery Questionnaire (KVIQ) is a motor imagery questionnaire developed for individuals with limited mobility for different reasons. The questionnaire assesses both the visual and kinesthetic dimensions of motor imagery. of the KVIQ; It has also been shown in the literature that it is a valid and reliable questionnaire that enables the appropriate evaluation of motor imagery in different neurological disease groups such as Multiple Sclerosis, Parkinson's disease, and stroke. However, the literature When examined, no evidence was found about the motor imagery ability of individuals with Duchenne muscular dystrophy (DMD). It is foreseen that KVIQ will be especially suitable for patients with DMD of different functional levels, since all its items have been developed to be applied to people with limited physical mobility or physically disabled people in a sitting position. Therefore, in this study, it is aimed to investigate the validity and reliability of the Kinesthetic and Visual Imagery Questionnaire for patients with DMD.

Condition or disease
Duchenne Muscular Dystrophy

Detailed Description:

DMD and age matched healthy individuals will be participate the study between the ages of 7 and 18 years.

Children who cannot cooperate with the physiotherapist adequately and who have had any injury and/or surgery to the lower/upper extremities in the last 6 months will not be included in the study.

Study Design

• Study Type: Observational
• Estimated Enrollment: 100 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Investigation of the Validity and Reliability of the Kinesthetic and Visual Imagery Questionnaire in Children With Duchenne Muscular Dystrophy
• Estimated Study Start Date: November 2022
• Estimated Primary Completion Date: February 2023
• Estimated Study Completion Date: June 2023

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. Kinesthetic and Visual Imagery Questionnaire (KVIQ) [ Time Frame: 15 minutes ]
   he Kinesthetic and Visual Imagery Questionnaire is a representative tool to assess motor imagery ability. The questionnaire can be used to assess healthy individuals, as well as those with physical disabilities. It allows easy evaluation of motor imagery ability in a sitting position with single joint motions. Furthermore, the questionnaire assesses both visual and kinesthetic dimensions of motor imagery. The questionnaire is not self-administered, rather it is administered by a trained assessor. It assesses the vividness of each dimension of motor imagery (clarity of the image/intensity of sensation) on a 5-point ordinal scale.The long version comprises 20 items (10 movements for each scale) and the short version includes 10 items (5 movements for each scale). Higher scores mean a better outcome.

Secondary Outcome Measures :

1. Movement Imagery Questionnaire-Children(MIQ-C) [ Time Frame: 20 minutes ]
   Visual and Kinesthetic motor imagery ability will be evaluated with MIQ-C. Includes 12 items in total. The individual is asked to visualize four different movements from three different imagery perspectives. The clearness of the imagination is scored using a Likert-type scale between 1 (very difficult to feel) -7 (very easy to feel)
2. Modified Mini Mental Test (MMMT) [ Time Frame: 5 minutes ]
   This test; orientation, memory (recording), attention and calculation, recall and language subtests. The highest score that can be obtained from MMMT is 35. The application time of the test is approximately 5-10 minutes. It has been reported that this test is a suitable tool for the examination of mental functions from the age of 4 and can be easily included in routine neurological examinations of children. Children between the ages of 7 and 15 who get 27 points below the MMMT will be excluded from the study. Children's total score will be recorded
3. Mini Mental State Test [ Time Frame: 5 minutes ]
   A mini mental state test will be used to evaluate the mental state of children aged 16-18. Test; It evaluates verbal responses including attention, orientation, memory and language skills, ability to obey verbal and written orders, write spontaneous sentences, and copy a complex drawing. The maximum score that can be obtained from the test is 30, the minimum score is 0.
4. Montreal Cognitive Assessment Scale (MoCA) [ Time Frame: 10 minutes ]
   In this test, which was developed as a rapid screening test for mild cognitive disorders; 8 different cognitive functions are evaluated, including attention, concentration, executive functions, memory, language, visual construction skills, abstract thinking, calculation and orientation. The application time of MoCA, which evaluates abstract thinking in addition to the other test, is approximately 10 minutes. The minimum score that can be taken from the test is 0 and the maximum score is 30. Accordingly, a score of 21 and above indicates normal cognitive functions.

Eligibility Criteria

• Ages Eligible for Study: 7 Years to 18 Years (Child, Adult)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Because DMD is X linked recessive disorder, this disorder is seen in male
• Accepts Healthy Volunteers: Yes
• Sampling Method: Probability Sample

Study Population

Duchenne Muscular Dystrophy (DMD), X-linked recessive It is a genetic disease that is inherited and has a prevalence of approximately 1/3600-6000 live male births. The disorder is caused by a mutation in the dystrophin gene located on the X chromosome, resulting in complete or partial absence of the dystrophin protein in the cell membrane, resulting in irreversible progressive loss of functional abilities. The symptoms are manifested by gait disturbance between 3-5 years of age, primarily due to progressive weakness in the proximal muscles. Delayed gait, toe walking, duck-like gait, difficulty climbing stairs and running are early signs of Gower's sign. Gait begins to deteriorate between the ages of 3 and 6, and patients become wheelchair dependent at around 10-12 years of age.

Criteria

Inclusion Criteria:

• Having a diagnosis of DMD confirmed by a genetic test result,
• Be between the ages of 7-18,
• More than 27 (27-35 indicates normal cognitive level) from the Modified Mini Mental Test of children aged 7-15 years to be able to cooperate with the physiotherapist's instructions; Children between the ages of 16-18 get more than 24 points from the Mini Mental State Test (24-30 points indicate no cognitive impairment, 20-23 indicates mild, 10-19 moderate, and below 9 indicates severe cognitive impairment),
• Ability to sit for at least 30 minutes with/without support,
• Volunteering to participate in the study.

Exclusion Criteria:

• Insufficient cooperation with the physiotherapist,
• Any injury and/or surgery to the lower/upper extremities in the last 6 months
• Having any additional neurological/orthopedic problems other than DMD.

Contacts and Locations

No Contacts or Locations Provided

More Information

• Responsible Party: Merve Bora, Physiotherapist, Hacettepe University
• ClinicalTrials.gov Identifier: NCT05559710
• Other Study ID Numbers: GO 22/750
• First Posted: September 29, 2022
• Last Update Posted: November 8, 2022
• Last Verified: November 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked